657 reports of this reaction
3.4% of all LISINOPRIL AND HYDROCHLOROTHIAZIDE reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for LISINOPRIL AND HYDROCHLOROTHIAZIDE, manufactured by Almatica Pharma Inc.. There are 657 FDA adverse event reports linking LISINOPRIL AND HYDROCHLOROTHIAZIDE to FATIGUE. This represents approximately 3.4% of all 19,221 adverse event reports for this drug.
Patients taking LISINOPRIL AND HYDROCHLOROTHIAZIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among LISINOPRIL AND HYDROCHLOROTHIAZIDE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for LISINOPRIL AND HYDROCHLOROTHIAZIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 657 FDA reports for LISINOPRIL AND HYDROCHLOROTHIAZIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.4% of all adverse event reports for LISINOPRIL AND HYDROCHLOROTHIAZIDE, making it one of the most commonly reported side effect.
If you experience fatigue while taking LISINOPRIL AND HYDROCHLOROTHIAZIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.